Article Text

Download PDFPDF

LP-013 Autoantibody trajectories associate with classification and treatment response in lupus nephritis
  1. Andrea Fava1,
  2. Carla Guthridge2,
  3. Joseph Kheir3,
  4. Catriona Wagner3,
  5. Michelle Petri1,
  6. Jill Buyon4,
  7. Betty Diamond5,
  8. The Accelerating Medicine Partnership in ra/sle6,
  9. Joel Guthridge2 and
  10. Judith James2
  1. 1Division of Rheumatology, Johns Hopkins University, USA
  2. 2Rheumatology, Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences, USA
  3. 3Rheumatology, Oklahoma Medical Research Foundation, USA
  4. 4Rheumatology, New York University, USA
  5. 5Feinstein Institutes for Medical Research, Northwell Health, USA
  6. 6Multiple Institutions, Multiple Institutions, USA


Background Autoantibodies are a hallmark of lupus nephritis (LN). While there is known heterogeneity in autoantibody expression among LN patients, the association of autoantibodies with LN subtypes and the implications of longitudinal changes in LN are not entirely understood. In this study, we quantified circulating autoantibodies in the Accelerating Medicines Partnership (AMP) LN longitudinal cohort to identify novel serum biomarkers of LN classification and treatment response and to provide insights into the pathogenesis of LN.

Methods SLE patients meeting ACR or SLICC criteria (n=268) indicated for kidney biopsy by a urine protein/creatinine (UPCR) >0.5 were recruited for this study as part of the AMP. Kidney biopsies were evaluated by a renal pathologist according to ISN/RPS classification, and serum samples were collected at the time of diagnostic kidney biopsy and 3-, 6-, and 12-months post-biopsy. Serum autoantibodies against dsDNA, chromatin, ribosomal-P, Ro, La, Sm, SmRNP, RNP, Jo-1, Scl-70, and centromere-B were measured using the BioPlex 2200® ANA kit (Bio-Rad Technologies, Hercules, CA), while anti-C1q positivity was determined by ELISA (QUANTA Lite®, Werfen, Bedford, MA). Clinical response was determined at 12 months using the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study definitions for patients with ISN/RPS class III, IV, V, or a combination thereof and a baseline UPCR ratio >1.0.

Results Most LN patients exhibited autoantibodies against chromatin (78%) dsDNA (70%), SmRNP (63%), C1q (56%), RNP (54%), and Sm (52%) (figure 1A). Patients with proliferative LN (class III, IV, III+V, or IV+V) had higher positivity rates of several autoantibodies, including those against dsDNA, chromatin, and C1q, compared to patients with membranous LN (class V) (figure 1A). Similarly, patients with pure proliferative (class III or IV) and mixed (class III+V or IV+V) LN had significantly higher titers of these autoantibodies compared to those with mesangial (class I or II), membranous, and advanced sclerosis (class VI) LN (figure 1B-D). Furthermore, increased titers of these autoantibodies were associated with higher odds of having proliferative LN (table 1). Proliferative LN patients with a complete treatment response exhibited a significant decline in several autoantibodies including anti-dsDNA, C1q, chromatin, Smith, and ribosomal P (figure 1F). Autoantibody levels remained relatively stable in partial- and non-responder proliferative LN patients, as well as in patients with membranous LN.

Conclusions LN patients exhibit heterogeneous autoantibody profiles associated with ISN/RPS classification. Specifically, levels of autoantibodies against dsDNA, C1q, chromatin, and ribosomal P may serve as noninvasive biomarkers of proliferative LN. In patients with proliferative but not membranous LN, a decline in the titers of several autoantibodies, including many not routinely measured over time, such as anti-Sm, was associated with treatment response, suggesting a possible role in LN pathogenesis. In addition, these autoantibodies may serve as early biomarkers of treatment response.

Abstract LP-013 Table 1
  • lupus nephritis
  • autoantibodies
  • AMP

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.